Vaxart, Inc.’s Oral H1N1 Influenza Vaccine Generates Protective Immunity

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SAN FRANCISCO--(BUSINESS WIRE)--Vaxart, a privately held company developing recombinant vaccines that are administered by tablet rather than by injection, today announced positive safety and immunogenicity data from a phase Ib clinical dose-ranging study with its oral H1N1 seasonal influenza vaccine candidate. This study follows a phase I study, the positive results of which were announced in June 2013.

Help employers find you! Check out all the jobs and post your resume.

Back to news